Astrazeneca Pharma India Shares Dive Nearly 7% As Vaccine Trials Paused

AstraZeneca Pharma India shares dived nearly 7 per cent on Wednesday, after its parent company, AstraZeneca, "voluntarily paused" a randomised clinical trial of its coronavirus vaccine, citing unexplained illness of a volunteer. The AstraZeneca Pharma stock declined by as much as 13.40 per cent - or Rs 64.80 - to Rs 3,650 apiece at the weakest level recorded on the BSE during the session, having started the day weaker at Rs 3,800 com...